Endonovo TherapeuticsENDV Owner Earnings per Share (TTM) is 0.00 as of Jun. 2025. Among 207 Biotechnology companies, Endonovo Therapeutics ranks worse than 483091.3% on this metric.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Endonovo Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as Price-to-Owner-Earnings ratio.
The historical rank and industry rank for Endonovo Therapeutics's Owner Earnings per Share (TTM) or its related term are showing as below:
ENDV's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 24.32 * Ranked among companies with meaningful Price-to-Owner-Earnings only.
Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.
Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.
Endonovo Therapeutics Owner Earnings per Share (TTM) Related Terms
Endonovo Therapeutics Owner Earnings per Share (TTM) Historical Data
* Premium members only.
The historical data trend for Endonovo Therapeutics's Owner Earnings per Share (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Endonovo Therapeutics Owner Earnings per Share (TTM) Chart
ENDV vs RGBP, SIGY, CNBX: Owner Earnings per Share (TTM) Comparison
For the Biotechnology subindustry, Endonovo Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Endonovo Therapeutics Price-to-Owner-Earnings vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Endonovo Therapeutics's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
What does a Owner Earnings per Share (TTM) of 0.00 mean?
Endonovo Therapeutics (ENDV) has a Owner Earnings per Share (TTM) of 0.00 as of Jun. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Endonovo Therapeutics. According to the industry distribution chart, Endonovo Therapeutics ranks #999999 out of 207 companies in the Biotechnology industry.
Is Endonovo Therapeutics' Owner Earnings per Share (TTM) too high?
Endonovo Therapeutics' current Owner Earnings per Share (TTM) is 0.00. Based on the distribution chart, Endonovo Therapeutics ranks #999999 out of 207 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Endonovo Therapeutics' Owner Earnings per Share (TTM) compare to RGBP and SIGY?
According to the Biotechnology industry distribution chart, Endonovo Therapeutics ranks #999999 out of 207 companies for Owner Earnings per Share (TTM). This places Endonovo Therapeutics in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 24.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Biotechnology company?
The median Owner Earnings per Share (TTM) among Biotechnology companies is 24.32, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Endonovo Therapeutics. For the Biotechnology industry, the median Owner Earnings per Share (TTM) is 24.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Endonovo Therapeutics's current Owner Earnings per Share (TTM) is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current Owner Earnings per Share (TTM) of 0.00. The current Owner Earnings per Share (TTM) is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current Owner Earnings per Share (TTM) is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENDV has been successfully added to your 